The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes
- PMID: 16846547
- DOI: 10.1185/030079906X104803
The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes
Abstract
Objective: To evaluate the efficacy and the tolerability of micronized purified flavonoid fraction (MPFF) on symptoms and signs of acute haemorrhoidal disease (HD).
Research design and methods: Patients experiencing an acute HD episode for less than 48 h were enrolled in this randomized, double-blind, placebo-controlled study (n = 90 in two hospital-based study centres in Beijing). One group received MPFF, six tablets per day for 4 days followed by four tablets per day for 3 days and the other a placebo. Symptoms and signs of HD were assessed by blinded observers at day 0 (D0), day 4 (D4), and day 7 (D7) on a 4-point severity grading scale (from 1 = absent to 4 = severe). A two-way variance analysis was performed for comparison between groups.
Results: Forty-nine patients (49) in the MPFF group and 41 in the placebo group (mean age 43.2 years [range 18-76 years]), percentage of male gender 54.4%, mean time from onset of acute episode 45.3 h (range 16-48 h) were included in this analysis. No significant differences between groups were seen at baseline in terms of age, gender, and frequency and intensity of symptoms, except for oedema, whose frequency and severity was significantly greater in the MPFF group (p = 0.024). During the 7-day treatment, there was a significant difference in favour of MPFF in the evolution of pain and oedema (p < or = 0.001 at D7) and in bleeding (p = 0.021 at D4, and p = 0.047 at D7). The appreciation of global efficacy by patients (p = 0.007) or investigators (p = 0.006) also favoured MPFF. Blood pressure, heart rate and laboratory parameters remained within normal ranges and were not modified during the study in either group. No patient had to stop the treatment owing to adverse events and only one patient reported gastrointestinal discomfort.
Conclusion: MPFF significantly reduced the extent of pain and bleeding in the selected subjects of this study with acute haemorrhoids. The tolerability was similar in patients receiving MPFF to that in patients receiving a placebo during the 7-day duration of the treatment.MPFF can be considered an effective and well-tolerated agent in the treatment of acute episodes of haemorrhoids.
Similar articles
-
Prospective, randomized, controlled, observer-blinded trial of combined infrared photocoagulation and micronized purified flavonoid fraction versus each alone for the treatment of hemorrhoidal disease.Clin Ther. 2005 Jun;27(6):746-54. doi: 10.1016/j.clinthera.2005.06.016. Clin Ther. 2005. PMID: 16117981 Clinical Trial.
-
Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids.Br J Surg. 2000 Jul;87(7):868-72. doi: 10.1046/j.1365-2168.2000.01448.x. Br J Surg. 2000. PMID: 10931020 Clinical Trial.
-
Clinical use of micronized purified flavonoid fraction for treatment of symptoms after hemorrhoidectomy: results of a randomized, controlled, clinical trial.Dis Colon Rectum. 2004 May;47(5):704-10. doi: 10.1007/s10350-003-0119-1. Epub 2004 Mar 25. Dis Colon Rectum. 2004. PMID: 15037936 Clinical Trial.
-
Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.Drugs. 2003;63(1):71-100. doi: 10.2165/00003495-200363010-00005. Drugs. 2003. PMID: 12487623 Review.
-
Micronized Purified Flavonoid Fraction in Hemorrhoid Disease: A Systematic Review and Meta-Analysis.Adv Ther. 2020 Jun;37(6):2792-2812. doi: 10.1007/s12325-020-01353-7. Epub 2020 May 12. Adv Ther. 2020. PMID: 32399811 Free PMC article.
Cited by
-
Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study.Int J Colorectal Dis. 2018 Nov;33(11):1595-1600. doi: 10.1007/s00384-018-3102-y. Epub 2018 Jun 22. Int J Colorectal Dis. 2018. PMID: 29934701 Clinical Trial.
-
A Prospective Study on the Efficacy of Two Different Phlebotonic Therapies as a Bridge to Surgery in Patients with Advanced Hemorrhoidal Disease.J Clin Med. 2021 Apr 7;10(8):1549. doi: 10.3390/jcm10081549. J Clin Med. 2021. PMID: 33917023 Free PMC article.
-
[Consensus statement haemorrhoidal disease].Wien Klin Wochenschr. 2012 Mar;124(5-6):207-19. doi: 10.1007/s00508-011-0107-8. Epub 2012 Mar 2. Wien Klin Wochenschr. 2012. PMID: 22378598 German.
-
Japanese Practice Guidelines for Anal Disorders I. Hemorrhoids.J Anus Rectum Colon. 2018 May 25;1(3):89-99. doi: 10.23922/jarc.2017-018. eCollection 2017. J Anus Rectum Colon. 2018. PMID: 31583307 Free PMC article. Review.
-
Evaluation of the Efficacy and Safety of a Compound of Micronized Flavonoids in Combination With Vitamin C and Extracts of Centella asiatica, Vaccinium myrtillus, and Vitis vinifera for the Reduction of Hemorrhoidal Symptoms in Patients With Grade II and III Hemorrhoidal Disease: A Retrospective Real-Life Study.Front Pharmacol. 2021 Dec 14;12:773320. doi: 10.3389/fphar.2021.773320. eCollection 2021. Front Pharmacol. 2021. PMID: 34970145 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical